Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 7.

Journal Article

Al-Sawaf, O., Bahlo, J., Fischer, K., Herling, C., Hoechstetter, M., Fink, A., von Tresckow, J., Langerbeins, P., Cramer, P., Stilgenbauer, S., Wendtner, C., Eichhorst, B., Hallek, M. and Goede, V. (2017). CHARACTERISTICS, TREATMENT, AND OUTCOMES OF >= 80 YEAR OLD PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) ENROLLED TO PROSPECTIVE TRIALS OF THE GERMAN CLL STUDY GROUP. Haematologica, 102. S. 421 - 422. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Al-Sawaf, O., Bahlo, J., Fischer, K., Herling, C., M., Hochstaetter, Fink, A. M., von Tresckow, J., Langerbeins, P., Cramer, P., Stilgenbauer, S., Wendtner, C. M., Eichhorst, B., Hallek, M. and Goede, V. (2017). Characteristics, treatment, and outcomes of >= 80 year old patients with chronic lymphocytic leukemia (CLL) enrolled to prospective trials of the German CLL study group. Oncol. Res. Treat., 40. S. 139 - 140. BASEL: KARGER. ISSN 2296-5262

Althoff, K., Leitzke, S., Herling, C., Frenzel, L., Schiller, J., Herling, M., Holtick, U., Scheid, C. and Theurich, S. (2018). Metabolic status and immune activation prior conditioning influence clinical outcomes in patients after allogeneic hematopoietic stem cell transplantation. Oncol. Res. Treat., 41. S. 66 - 67. BASEL: KARGER. ISSN 2296-5262

Fuerstenau, M., Fink, A-M, Herling, C., Maurer, C., Kutsch, N., de la Serna, J., Coscia, M., Eckert, R., Crespo, M., Bosch, F., Noesslinger, T., Ghia, P., Kater, A. P., Boettcher, S., Ritgen, M., Schilhabel, A., Stilgenbauer, S., Tausch, E., Fischer, K., Hallek, M. and Eichhorst, B. (2018). B-cell acute lymphoblastic leukemia (B-ALL) in CLL patients treated with lenalidomide. Oncol. Res. Treat., 41. S. 172 - 174. BASEL: KARGER. ISSN 2296-5262

Holtick, U., Herling, M., Theurich, S., Frenzel, L., Herling, C., Schiller, J., Hallek, M. and Scheid, C. (2018). A phase II study to investigate the efficacy of short-term everolimus in addition to post-transplant cyclophosphamide as graft-versus-host-prophylaxis after allogeneic hematopoietic stem cell transplantation (OCTET-EVER). Oncol. Res. Treat., 41. S. 63 - 64. BASEL: KARGER. ISSN 2296-5262

Knittel, G., Korovkina, D., Liedgens, P., Fritz, C., Al-Baldawi, Y., Bahlo, J., Herling, C., Eichhorst, B., Hallek, M., Persigehl, T., Buettner, R. and Reinhardt, H. C. (2016). ESTABLISHMENT OF A PRE-CLINICAL IN VIVO PLATFORM SPANNING LOW-RISK TO HIGH-RISK CLL. Haematologica, 101. S. 9 - 11. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Knittel, G., Korovkina, D., Liedgens, P., Rehkaemper, T., Fritz, C., Torgovnick, A., Al-Baldawi, Y., Al-Maarri, M., Cun, Y., Fedorchenko, O., Riabinska, A., Beleggia, F., Nguyen, P. -H., Wunderlich, F. T., Ortmann, M., Montesinos-Rongen, M., Tausch, E., Stilgenbauer, S., Frenzel, L., Herling, M., Herling, C., Bahlo, J., Hallek, M., Peifer, M., Buettner, R., Persigehl, T. and Reinhardt, H. C. (2017). Novel models of high-risk CLL reveal an actionable PARP1 dependence in ATM-defective CLL in vivo. Oncol. Res. Treat., 40. S. 27 - 28. BASEL: KARGER. ISSN 2296-5262

This list was generated on Thu Mar 28 18:31:26 2024 CET.